Makers Laboratories Ltd Valuation Shifts: From Attractive to Fair Amidst Sector Dynamics

Valuation Metrics and Recent Changes

As of 6 July 2026, Makers Laboratories Ltd trades at ₹151.45 per share, down 5.96% on the day from a previous close of ₹161.05. The stock’s 52-week high stands at ₹186.70, with a low of ₹109.00, indicating a wide trading range over the past year. The company’s P/E ratio currently sits at 38.03, a figure that has contributed to the downgrade in its valuation grade from attractive to fair. Meanwhile, the P/BV ratio is 1.23, suggesting the stock is valued slightly above its book value but remains reasonable compared to some peers.

Other valuation multiples include an EV to EBIT of 8.16 and an EV to EBITDA of 5.66, both indicative of moderate enterprise value relative to earnings. The EV to sales ratio is 0.59, reflecting a conservative valuation on a sales basis. Notably, the PEG ratio is reported as zero, which may indicate either a lack of earnings growth projection or data unavailability, warranting cautious interpretation.

Comparative Sector and Peer Analysis

Within the Pharmaceuticals & Biotechnology sector, Makers Laboratories Ltd is classified as a micro-cap entity, which often entails higher volatility and risk compared to larger peers. When benchmarked against competitors, Makers Labs’ valuation appears more moderate. For instance, Bliss GVS Pharma and Kwality Pharma are rated as very expensive with P/E ratios exceeding 41 and EV to EBITDA multiples above 24, signalling stretched valuations. Venus Remedies, with a P/E of 22.6 and EV to EBITDA of 15.16, is considered expensive but less so than the aforementioned peers.

Interestingly, Fredun Pharma is tagged as attractive despite a P/E ratio similar to Makers Labs at 38.1, but with a higher EV to EBITDA of 16.71 and a PEG ratio of 0.66, suggesting better growth prospects or operational efficiency. Syncom Formulations, with a P/E of 17.51 and EV to EBITDA of 15.84, is graded fair, indicating a more balanced valuation. This peer comparison highlights that while Makers Labs’ valuation has become less compelling, it remains relatively reasonable within its competitive set.

Financial Performance and Returns

Examining financial returns, Makers Laboratories Ltd has delivered mixed performance relative to the Sensex benchmark. Year-to-date, the stock has surged 28.18%, significantly outperforming the Sensex’s negative 8.75% return. Over three years, the stock has appreciated 35.59%, again surpassing the Sensex’s 19.26% gain. However, over five years, the stock has declined 22.43%, contrasting with the Sensex’s robust 48.16% growth, and over ten years, Makers Labs has returned 111.37% compared to the Sensex’s 186.48%.

These figures suggest that while Makers Labs has shown strong short- and medium-term momentum, its longer-term performance has lagged broader market indices. This disparity may influence investor sentiment and valuation adjustments.

Operational Efficiency and Profitability

From an operational standpoint, Makers Laboratories Ltd reports a return on capital employed (ROCE) of 15.26%, which is a respectable figure indicating efficient use of capital to generate earnings. However, the return on equity (ROE) is relatively low at 3.22%, signalling limited profitability for shareholders. This divergence between ROCE and ROE may reflect capital structure nuances or earnings retention policies, factors that investors should consider when assessing valuation.

Valuation Grade Downgrade and Market Implications

On 29 June 2026, Makers Laboratories Ltd’s Mojo Grade was downgraded from Hold to Sell, with a Mojo Score of 47.0. This downgrade reflects the shift in valuation grade from attractive to fair, signalling increased caution among analysts and investors. The downgrade is consistent with the stock’s recent price decline and the elevated P/E ratio relative to historical levels and some peers.

The downgrade also aligns with the company’s micro-cap status, which typically entails higher risk and less liquidity. Investors may interpret the fair valuation grade as a signal to reassess exposure, especially given the stock’s recent underperformance relative to its 52-week high and the broader market.

Sector Valuation Context and Risk Considerations

The Pharmaceuticals & Biotechnology sector has witnessed varied valuation trends, with several companies trading at very expensive multiples. Makers Labs’ current valuation, while less attractive than before, remains more moderate than many peers, which could appeal to value-conscious investors seeking exposure to the sector without excessive premium.

However, the company’s low ROE and micro-cap classification introduce risk factors that may temper enthusiasm. Additionally, the absence of dividend yield data suggests limited income generation, which may deter income-focused investors.

Investor Takeaways and Outlook

Investors analysing Makers Laboratories Ltd should weigh the recent valuation shift carefully. The move from attractive to fair valuation, combined with a downgrade to Sell, suggests that the stock’s price may have limited upside in the near term without a corresponding improvement in fundamentals or market sentiment.

While the company’s short-term returns have outpaced the Sensex, its longer-term underperformance and modest profitability metrics warrant caution. The relatively high P/E ratio compared to sector averages indicates that the market may be pricing in growth expectations that are yet to materialise fully.

For those seeking exposure to the Pharmaceuticals & Biotechnology sector, it may be prudent to consider alternatives with stronger valuation support or higher quality metrics. The sector’s broad valuation dispersion offers opportunities for selective investment based on comprehensive fundamental analysis.

Conclusion

Makers Laboratories Ltd’s recent valuation parameter changes reflect a nuanced market reassessment. The shift from attractive to fair valuation, driven primarily by elevated P/E and moderate P/BV ratios, aligns with a downgrade in analyst sentiment. While the company maintains respectable operational efficiency, its micro-cap status, low ROE, and relative valuation position suggest investors should approach with measured expectations. Comparative sector analysis underscores the importance of evaluating both valuation and quality metrics when considering investment in this segment.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →